30 closest matches · ranked by relevance
Focal Epilepsy
Primary: 58-week Retention Rate Measured by the Number of Drop Outs Due to Adverse Events or Seizures From Day 1 of Treatment — 0.61; 0.46; 0.56 proportion of participants…
Post Stroke Epilepsy
Primary: Proportion of Patients Who Experience the First Unprovoked Seizures (US) Within the First 6 Months After Randomisation (Failure Rate) — 2; 7; 3; 0 Participants
Epilepsy
Primary: Raw Count of Number of Days of Medication Nonadherence — 28 % of nonadherence days
Healthy
Primary: Difference in RAVLT Total T-Score Between Treatments — 57.76; 56.11; 53.08; 42.76 T-score — p=<0.01
Epilepsy · Post-traumatic Epilepsy
Primary: Post-Traumatic Epilepsy — 6; 8 participants
Depressive Disorder · Anhedonia
Primary: Change in Ventral Striatum (VS) Activation — -0.26; 0.95; 0.176; 0.015 Bold Oxygen-level Dependent (BOLD) Signa
Epilepsy
Primary: MMSE at Baseline and at Three (3) Months. — 18.2; 2.2 units on a scale — p=.01
Epilepsy
Primary: To Determine if the Frequency of Premenstrual Dysphoric Disorder Differs Among Various Antiepileptic Drug Monotherapies. — 0; 0; 0; 2 Participants
APOE 4
Primary: Functional Connectivity Strengths of Neural Networks — 0.233; 0.318 Pearson coefficient — p=0.007567
Schizophrenia; Psychosis
Primary: Hippocampal Activity (Arterial Spin Labeling [ASL] Study) After Levetiracetam (LEV) — 28.3; 27.1; 28.0; 28.5 ml/100g/min
Epilepsy
Primary: Sleep Latency Wakefulness After Sleep Onset (WASO) — 42.3; 57.3 minutes/night
Epilepsy
Primary: Average Annualized Costs — 1352; 462; 1357; 1050 United States dollars — p=<0.0001
Refractory Epilepsy
Primary: Change From Baseline in the Mean Number of Daily Seizures at 1 Year. — 9 Number of Seizures — p=<0.02
Tuberous Sclerosis Complex
Primary: Cognitive Assessment Scores and Developmental Impact — 83.9; 80.9; 97.3; 85.0 score on a scale — p=0.8681
Bipolar Disorder
Primary: Change in Serum Brain Derived Neurotrophic Factor (BDNF) — 23.1; 90.7 pg/ml
Reflex Epilepsy, Photosensitive
Primary: The Standardized Photosensitivity Range (SPR) in the Subject's Most Sensitive Eye Condition — 0.57; 1.38; 1.58; 6.80 Units on a scale
Schizophrenia
Primary: Neurocognitive Function — 73.68; 74.04; 3.36; 3.96 Total score
Epilepsy
Primary: Percentage of Responders During the Maintenance Phase — 44.4; 34.2; 55.6; 65.8 Percentage of Participants
Focal Epilepsy
Primary: Percent of Participants Classified as Responders — 76.7; 80.0 percent of participants — p=<0.0001
Partial Epilepsy · Catamenial Epilepsy
Primary: Mean Weekly Log-transformed Seizure Frequency During Weeks 1 Through 10 — 5.20; 10.77 log[seizures per week]
Cognitive Measures · Driving Simulator Performance
Primary: Number of Subjects Who Had a Driving Simulator Crash Event — 2; 0 Participants — p=0.50
Neuralgia · Epilepsy
Primary: Percentage of Participants With a 50 Percent or Greater Reduction From Baseline in 28 Day Partial Seizure Frequency — 85.00 Percentage of participants
Alzheimer's Disease
Primary: Imaging Biomarkers FDG-PET SUVR in Regions of Interest — -0.048; -0.005; -0.032; -0.007 Standardized Uptake Value Ratios (SUVRs)
Epilepsy
Primary: Functional Connectivity
Epilepsy · Cognitive Deficits · Attention Deficits
Primary: Conners' Continuous Performance Test (CPT) (Double-blind Portion, Primary Variables) — -3.3; -3.58; -3.66; 0.19 Units — p=0.037
Epilepsy
Primary: Mean Change in Focal Interictal Discharges (IEDs) Per Hour, Pre to Post Treatment — -28.8; .54 IEDs/hour — p=>0.05
Epilepsy
Primary: The Percentage of Participants With a 50% or Greater Reduction in Seizure Frequency (Further Referred to as "Responders") in a Treatment Period Compared to the Baseline…
Epilepsy · Contraception
Primary: Percent of Participants That Experienced Clinically Meaningful Change in Lamotrigine Level — 0 percentage of participants
Healthy
Primary: Change in Baseline Visual Evoked Potential (P100) Amplitude
Intracranial Aneurysms · Seizure
Primary: Incidence of Seizure — 2; 1; 0; 0 Participants